

## Special Issue

# Molecular Research in Breast Cancer

### Message from the Guest Editors

Breast cancer, one of the most common cancers affecting women worldwide, is classified based on its histological and molecular variability. This variability influences prognosis and treatment strategies, making breast cancer a complex disease to study and manage. The Special Issue, titled “Molecular Research in Breast Cancer,” aims to collect recent findings in this context, such as the following:

- Genetic, epigenetic, and transcriptional profiles;
- Descriptions of proteomic features and biochemical pathways;
- Identification of cancer stem cells and their interactions with the microenvironment;
- Metabolic reprogramming;
- Effects induced by various drugs, in vitro and in vivo;
- Breast cancer immunity and metabolic reprogramming;
- Any evidence useful in identifying novel molecular targets to address the aggressive nature of triple-negative breast cancer (TNBC).

We welcome contributions that enhance our understanding of breast cancer at the molecular level, providing insights that could lead to more effective treatments and improved patient outcomes.

---

### Guest Editors

Dr. Anna De Blasio

Laboratory of Biochemistry, Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, 90127 Palermo, Italy

Dr. Daniela Carlisi

Section of Biochemistry, Department of Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, 90127 Palermo, Italy

---

### Deadline for manuscript submissions

31 August 2026



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/213244](https://mdpi.com/si/213244)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).